Journal Article Summary
The article investigates the effectiveness, safety, and acceptability of using levonorgestrel (LNG) 1.5 mg as a pericoital oral contraceptive, which means it is taken around the time of sexual intercourse. This topic is significant because many women have infrequent sexual encounters and may prefer a contraceptive method that does not require daily use. The study aims to provide insights into a potential alternative to traditional daily oral contraceptives, which could be more convenient and intuitive for some women.
In this study, 330 healthy women aged 18 to 45, who reported having sexual intercourse on up to six days a month, participated in a multicenter trial across four countries. Each participant took LNG 1.5 mg before or within 24 hours after sexual intercourse and maintained a diary to track their usage and any side effects. The results indicated a pregnancy rate of 7.1 pregnancies per 100 woman-years during typical use, suggesting that this method can be an effective contraceptive option for women who have infrequent sex. Additionally, most participants found the method acceptable and expressed a willingness to use it in the future.
However, the study has limitations, including its small sample size and lack of a control group, which may affect the generalizability of the findings. While the side effects reported were mostly mild, it is important for patients to discuss any concerns or questions about using LNG as a contraceptive with their healthcare provider. This conversation can help ensure that individuals make informed choices about their contraceptive options based on their specific health needs and circumstances.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Festin Mario P.R., Bahamondes Luis, Nguyen Thi My Huong, Habib Ndema, Thamkhantho Manopchai, Singh Kuldip, Gosavi Arundhati, Bartfai Gyorgy, et al.. A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg. Human Reproduction (Oxford, England) 2016. DOI: 10.1093/humrep/dev341. PMID: 26830816. PMCID: PMC4755445.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
